Association Between Type 2 Diabetes Mellitus and Heart Failure: A Retrospective Study from a Tertiary Care Diabetes Centre in India.

IF 3.8 3区 医学 Q2 Medicine
Rajendra Pradeepa, Thyparambil Aravindakshan PramodKumar, Ranjit Mohan Anjana, Saravanan Jebarani, Abdul Subhan Naziyagulnaaz, Sadasivam Ganesan, Natarajan Premananth, Abraham Oomman, Soumitra Kumar, Pathiyil Balagopalan Jayagopal, Gurpreet Singh Wander, Ajit Mullasari, Jagat Narula, Sanjay Jain, Onkar C Swami, Viswanathan Mohan
{"title":"Association Between Type 2 Diabetes Mellitus and Heart Failure: A Retrospective Study from a Tertiary Care Diabetes Centre in India.","authors":"Rajendra Pradeepa, Thyparambil Aravindakshan PramodKumar, Ranjit Mohan Anjana, Saravanan Jebarani, Abdul Subhan Naziyagulnaaz, Sadasivam Ganesan, Natarajan Premananth, Abraham Oomman, Soumitra Kumar, Pathiyil Balagopalan Jayagopal, Gurpreet Singh Wander, Ajit Mullasari, Jagat Narula, Sanjay Jain, Onkar C Swami, Viswanathan Mohan","doi":"10.1007/s13300-025-01746-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The study aimed to explore the association between type 2 diabetes (T2D) and heart failure (HF) using echocardiography and NT-proBNP. The study also derived an NT-proBNP cut-off for diagnosing HF by echo in Asian Indians with T2D.</p><p><strong>Methods: </strong>A retrospective study was performed using data from individuals with T2D, aged ≥ 18 years, who visited diabetes clinics in India between March 2019 and December 2023. NT-proBNP levels were quantified by chemiluminescence, and left ventricular ejection fraction (LVEF) was assessed from echo using two-dimensional (2D) echocardiography. Heart failure was classified based on the European Society of Cardiology (ESC) guidelines. Receiver operating characteristic (ROC) curve was performed to determine the optimal NT-proBNP cut-off for diagnosing HF by echo.</p><p><strong>Results: </strong>Among the 1189 study individuals included in the study (714 men and 475 women), 5.9% were identified as having HF with reduced ejection fraction (HFrEF), 5.5% had mildly reduced ejection fraction (HFmrEF), and 14.1% had HF with preserved ejection fraction (HFpEF) while the rest (74.5%) had LVEF > 50%. Elevated NT-proBNP levels were observed in those with reduced ejection fraction. ROC analysis identified an optimal NT-proBNP threshold of 398 pg/mL for diagnosing HF, with 87% sensitivity and 78% specificity. HF prevalence increased with age, peaking at 30.6% in individuals aged 61-70 years. Women with HF had higher NT-proBNP levels than men.</p><p><strong>Conclusions: </strong>In this diabetes clinic population, 11.5% of individuals with T2D had moderate to reduced LVEF. Early identification of HF using echocardiography and NT-proBNP in a diabetes clinic could help improve prognosis.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13300-025-01746-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The study aimed to explore the association between type 2 diabetes (T2D) and heart failure (HF) using echocardiography and NT-proBNP. The study also derived an NT-proBNP cut-off for diagnosing HF by echo in Asian Indians with T2D.

Methods: A retrospective study was performed using data from individuals with T2D, aged ≥ 18 years, who visited diabetes clinics in India between March 2019 and December 2023. NT-proBNP levels were quantified by chemiluminescence, and left ventricular ejection fraction (LVEF) was assessed from echo using two-dimensional (2D) echocardiography. Heart failure was classified based on the European Society of Cardiology (ESC) guidelines. Receiver operating characteristic (ROC) curve was performed to determine the optimal NT-proBNP cut-off for diagnosing HF by echo.

Results: Among the 1189 study individuals included in the study (714 men and 475 women), 5.9% were identified as having HF with reduced ejection fraction (HFrEF), 5.5% had mildly reduced ejection fraction (HFmrEF), and 14.1% had HF with preserved ejection fraction (HFpEF) while the rest (74.5%) had LVEF > 50%. Elevated NT-proBNP levels were observed in those with reduced ejection fraction. ROC analysis identified an optimal NT-proBNP threshold of 398 pg/mL for diagnosing HF, with 87% sensitivity and 78% specificity. HF prevalence increased with age, peaking at 30.6% in individuals aged 61-70 years. Women with HF had higher NT-proBNP levels than men.

Conclusions: In this diabetes clinic population, 11.5% of individuals with T2D had moderate to reduced LVEF. Early identification of HF using echocardiography and NT-proBNP in a diabetes clinic could help improve prognosis.

2型糖尿病和心力衰竭之间的关系:来自印度三级保健糖尿病中心的回顾性研究
本研究旨在利用超声心动图和NT-proBNP技术探讨2型糖尿病(T2D)与心力衰竭(HF)之间的关系。该研究还推导出一种NT-proBNP截止值,用于诊断亚洲印度T2D患者的心衰。方法:回顾性研究使用了2019年3月至2023年12月期间在印度糖尿病诊所就诊的年龄≥18岁的T2D患者的数据。用化学发光法定量NT-proBNP水平,用二维超声心动图评估左室射血分数(LVEF)。根据欧洲心脏病学会(ESC)指南对心力衰竭进行分类。采用受试者工作特征(ROC)曲线确定超声诊断HF的最佳NT-proBNP截止值。结果:在纳入研究的1189名研究个体(714名男性和475名女性)中,5.9%被确定为HF伴射血分数降低(HFrEF), 5.5%为轻度射血分数降低(HFmrEF), 14.1%为HF伴射血分数保留(HFpEF),其余(74.5%)为LVEF bb0 50%。在射血分数降低的患者中观察到NT-proBNP水平升高。ROC分析确定诊断HF的最佳NT-proBNP阈值为398 pg/mL,灵敏度为87%,特异性为78%。HF患病率随着年龄的增长而增加,在61-70岁的人群中达到30.6%的峰值。女性HF患者NT-proBNP水平高于男性。结论:在该糖尿病临床人群中,11.5%的T2D患者LVEF中度至降低。在糖尿病临床早期使用超声心动图和NT-proBNP识别心衰有助于改善预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Diabetes Therapy
Diabetes Therapy Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
6.90
自引率
7.90%
发文量
130
审稿时长
6 weeks
期刊介绍: Diabetes Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all areas of diabetes. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Diabetes Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信